"Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast - 2034"The chronic obstructive ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a study titled A Multicentre, ...

Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...

Finding the right dosages and combination of medications to treat chronic obstructive pulmonary disease (COPD) often requires an approach known as stepwise treatment. This method involves adding ...

This chronic lung disease limits air flow and causes breathing-related symptoms. While there is no cure, an innovative treatment option is helping some patients with severe COPD or emphysema ...

FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies ...

Chronic obstructive pulmonary disease (COPD) is a group of diseases that affect the lungs. The disease makes it difficult to breath and progressively gets worse.

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials ...

This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes.

Chronic Bronchitis and Emphysema are two COPD conditions with similar causes but distinct symptoms. Learn about their unique symptoms, causes, and treatments.